Brinzolamide/timolol fixed combination for open-angle glaucoma and ocular hypertension

Holló, Gábor

doi:10.1586/eop.09.7

Cited by 5 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than three times as many patients in the brinzolamide-timolol group reported no ocular discomfort after one week of therapy (49% versus 15%). Both groups had a statistically significant mean increase in ocular discomfort scores from baseline; however, the increase was less pronounced in the brinzolamide-timolol group 16,25,33…”

Section: Patient-focused Perspectivesmentioning

confidence: 88%

“…The most common nonocular adverse effect of the combination brinzolamide-timolol was dysgeusia (1.1%), which had a lower occurrence than treatment with brinzolamide alone (4.6%). Additionally, 1.1% had a decrease in blood pressure, 0.6% experienced exacerbation of chronic obstructive pulmonary disease, and 0.6% had pharyngolaryngeal pain 14,25…”

Section: Safetymentioning

confidence: 99%

“…Fixed combination medications simplify dosing by just having one bottle to use (and to refill) and they also decrease the frequency of applications. All of these factors may have a positive impact on patient compliance and IOP control 23,25…”

Section: Patient-focused Perspectivesmentioning

confidence: 99%

“…Brinzolamide-timolol caused more transient blurred vision and dorzolamide-timolol had more reported ocular irritation and pain. However, it seems patients preferred transient blurring of vision over ocular pain or discomfort 16,25,32…”

Section: Patient-focused Perspectivesmentioning

confidence: 99%

“…Additionally, 1.1% had a decrease in blood pressure, 0.6% experienced exacerbation of chronic obstructive pulmonary disease, and 0.6% had pharyngolaryngeal pain. 14 , 25 …”

Section: Safetymentioning

confidence: 99%

See 4 more Smart Citations

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension

Syed¹,

Loucks²

2011

OPTH

View full text Add to dashboard Cite

Glaucoma encompasses a wide clinical spectrum of disease, with the common pathophysiology of progressive optic neuropathy leading to visual field loss. Elevated intraocular pressure (IOP) is a key risk factor in disease progression. Treatment is aimed at reduction of IOP to minimize continued optic nerve head damage. Pharmacologic treatment with various classes of IOP-lowering medications is generally employed before more aggressive surgical interventions. Monotherapy is generally accepted as initial therapy for glaucoma, but at least half of patients may require more than one IOP-lowering medication. One option is the fixed combination of brinzolamide 1% and timolol maleate 0.5%, which is commercially available in some countries as Azarga® for treatment of glaucoma not adequately responsive to monotherapy. These agents may also be used in an unfixed fashion, but fixed combination therapy is generally more convenient for patients, which may result in improved compliance, a reduction of the “washout effect” from instilling multiple drops, and a potential reduction in the side effects related to multiple doses of preservatives.

show abstract

Section: Patient-focused Perspectivesmentioning

confidence: 88%

Section: Safetymentioning

confidence: 99%

Section: Patient-focused Perspectivesmentioning

confidence: 99%

Section: Patient-focused Perspectivesmentioning

confidence: 99%

“…Additionally, 1.1% had a decrease in blood pressure, 0.6% experienced exacerbation of chronic obstructive pulmonary disease, and 0.6% had pharyngolaryngeal pain. 14 , 25 …”

Section: Safetymentioning

confidence: 99%

See 3 more Smart Citations